, , Featured, Research, Video
Watch the MINT Clinical Trial for Myositis Patients with Interstitial Lung Disease webinar with Dr. Rohit Aggarwal. This clinical...
Join Dr. Rohit Aggarwal and MSU for a webinar about The MINT Clinical Trial for Myositis Patients with Interstitial...
Priovant Therapeutics joins MSU to discuss The Valor Study for Dermatomyositis, a phase 3 clinical trial for Adult Dermatomyositis....
, , Dermatomyositis, Featured, Video
We hosted Priovant Therapeutics to discuss The Valor Study, a phase 3 clinical trial for adult dermatomyositis. Learn all...
Please join us for a webinar about the new VALOR study. The purpose of the VALOR Study is to...
Kezar Announces Topline Results from the PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
Watch the recording with Alexion Pharmaceuticals to learn about the Flex Study to evaluate the safety and efficacy of...
Join MSU with Sanjay Rakhade MD, PhD, Executive Medical Director at Alexion Astra Zeneca Rare Disease Unit to learn...
MSU is hosting the first FDA Listening Session on Adult Dermatomyositis on April 26, 2022. We hope the FDA will come...
, , Dermatomyositis, Featured, Research
Corbus releases topline results for the phase 3 study of lenabasum in dermatomyositis. While it didn't meet the primary...
, , Featured, Inclusion Body Myositis (IBM), News
Learn more about the announcement from Orphazyme, communicating the topline results from the Phase 2/3 trial of arimoclomol for...
, , Dermatomyositis, Featured, Necrotizing Autoimmune Myopathy, Polymyositis, Video
Clinical trials are a key research tool for advancing medical knowledge and patient care. Join Kezar Life Sciences as...
Clinical trials are a key research tool for advancing medical knowledge and patient care. Join Kezar Life Sciences as...
Third Annual “A Day of Remembrance” a video event to honor and remember those we have lost with myositis....
Educational and engaging discussion w/ Dr. Andrew Mammen around immune-mediated necrotizing myopathy (IMNM) and the phase 2 clinical trial...
, , Featured, Inclusion Body Myositis (IBM), News
Information from Orphazyme A/S about the Clinical Development of Arimoclomol in sIBM during the COVID-19 Pandemic. Read a statement...
, , Featured, Video
Dr. Mary Katherine (MK) Farmer, MD, Rheumatologist and Senior Medical Director at Kezar Life Sciences, joined us live online...
, , Featured, Inclusion Body Myositis (IBM)
Orphazyme's Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis, an incurable rare progressively debilitating muscle-wasting disease...
, , Featured, Video
Ben Matys, Sr. Clinical Trial Manager, and Ramin Farzaneh-Far, Chief Medical Officer of Ra Pharma, joined MSU) on November...
, , Featured, Necrotizing Autoimmune Myopathy, News
We are excited to announce our partnership with Ra Pharma for RA101495-02.202: A Phase 2 Study of Zilucoplan in...
Earn donations to Myositis Support and Understanding Association at no added cost to you by using goodshop.
© 2023 Myositis Support and Understanding Association (MSU). All rights reserved. | View our Privacy Policy, Terms, and Non-Discrimination policy. MSU is a charitable organization with 501(c)(3) tax-exempt status. Federal ID #47-4570748.
View COVID-19 resources and updates, and stay tuned to your state, local, and federal health agencies, along with the CDC.
